Klaria Pharma Holding
0.612 SEK -8.66%1 investor is following this company
Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient's oral mucosa, which enables the distribution of pharmaceuticals in the body. The head office is located in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
KLAR
Daily low / high price
0.582 / 0.67
SEK
Market cap
88.59M SEK
Turnover
164.24K SEK
Volume
268K
Financial calendar
Interim report
21.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Ålandsbanken | 6.7 % | 6.7 % |
Skandinaviska Enskilda Banken | 4.3 % | 4.3 % |
Promenaden Invest AB | 3.8 % | 3.8 % |
Djerdu Invest AB | 3.8 % | 3.8 % |
Jack Weil | 3.8 % | 3.8 % |
Fredrik Hübinette | 3.6 % | 3.6 % |
Munkekullen Förvaltnings AB | 3.5 % | 3.5 % |
Sven-Olov Hjälmstad | 3.5 % | 3.5 % |
Buntel AB | 3.5 % | 3.5 % |
Banque Pictet & CIE | 3.3 % | 3.3 % |
ShowingAll content types
Klaria Pharma Holding AB: Klaria Interim Report Q2 2024
Klaria Pharma Holding AB: Klaria Sumatriptan Alginate Film Receives Marketing Authorization
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools